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ABSTRACT 51 
Limb amputation in the newt induces myofibers to dedifferentiate and re-enter 52 
the cell cycle to generate proliferative myogenic precursors in the regeneration 53 
blastema.  Here we show that Bone Morphogenetic Proteins (BMP) and mature 54 
BMPs that have been further cleaved by serum proteases induce cell cycle entry 55 
by dedifferentiating newt muscle cells.  Protease-activated BMP4/7 56 
heterodimers that are present in serum strongly induced myotube cell cycle re-57 
entry with protease cleavage yielding a thirty-fold potency increase of BMP4/7 58 
compared to canonical BMP4/7. Inhibition of BMP signaling via muscle-specific 59 
dominant-negative receptor expression reduced cell cycle entry in vitro, and in 60 
vivo.  In vivo inhibition of serine protease activity depressed cell cycle reentry, 61 
which in turn was rescued by cleaved-mimic BMP.   This work identifies a 62 
mechanism of BMP activation that generates blastema cells from differentiated 63 
muscle. 64 
 65 
 66 
 67 
 68 
69 
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INTRODUCTION 70 
 71 
In several regeneration contexts, cells of mature phenotype re-enter the cell 72 
cycle to help regenerate missing structures.  After lentectomy in the newt, dorsal 73 
iris pigmented epithelial cells (PEC) lose pigmentation, re-enter the cell cycle and 74 
transdifferentiate to regenerate the lens (Okada, 1991) (Grogg et al., 2005). 75 
During heart regeneration, cardiac myocytes re-enter the cell cycle and 76 
apparently expand to replace injured tissue (Jopling et al., 2010; Kikuchi et al., 77 
2010). During newt limb regeneration, skeletal muscle fibers dedifferentiate by 78 
cellularization of syncytial muscle fibers, down-regulation of muscle-specific 79 
proteins, and re-entry into the cell cycle to generate proliferative blastema cells, 80 
a process involving cell death-related pathways (Sandoval-Guzman et al., 2014) 81 
(Wang et al., 2015). The molecular pathways that initiate proliferation of 82 
dedifferentiating skeletal muscle and how the signal is activated by limb 83 
amputation remains poorly characterized.  Recent findings have identified a 84 
MARCKS (Myristoylated alanine-rich C-kinase substrate)-like protein as an 85 
epithelially-expressed factor that stimulates proliferation of both resident stem 86 
cells as well as of dedifferentiated myofibre progeny (Sugiura et al., 2016). Given 87 
that the repression of many of the canonical signalling pathways inhibits 88 
regeneration, the possibility that injury-activation of a canonical pathway was 89 
also involved lay open (Beck et al., 2001; Lin and Slack, 2008) (Poss, 2010).  90 
 91 
The local activities of serum proteases that regulate blood clotting are associated 92 
with initiation of regeneration. Regenerating newt limbs show localization of 93 
thrombin proteolytic activity (Tanaka et al., 1999) and inhibition of thrombin 94 
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activity repressed iris PEC proliferation (Imokawa and Brockes, 2003) (Godwin 95 
et al., 2010).  In vitro, newt skeletal myotubes re-entered cell cycle after exposure 96 
to serum, an effect that was strongly potentiated by thrombin and plasmin 97 
treatment (Tanaka et al., 1999; Tanaka et al., 1997).  These results implied that 98 
circulating plasma contains a cell cycle inducing activity that is highly activated 99 
by proteolytic cleavage.  Biochemical characterization and partial purification of 100 
the activity indicated that it is a high molecular weight glycoprotein with defined 101 
chromatographic properties (Straube et al, 2004).   102 
 103 
An important goal motivated by these results has been to identify the substrates 104 
of clotting proteases that induce cell cycle re-entry during regeneration. Is there 105 
a growth stimulatory factor that is a direct protease target, or do serum 106 
proteases act indirectly by cleaving an inhibitor? Here by assaying newt skeletal 107 
myotube cell cycle re-entry we show that BMP4-containing heterodimers as the 108 
major serum component required and sufficient for myotube cell cycle re-entry. 109 
We further show that BMPs have at least two major cleavage sites that are 110 
differentially sensitive to thrombin and plasmin. The combined cleavage results 111 
in up to thirty-fold potency increase of BMP4/7. In vivo blockage of BMP 112 
signaling specifically in dedifferentiating muscle fibers negatively affects S-phase 113 
entry.  Furthermore, the in vivo inhibition of serum protease activity depresses 114 
the BMP-dependent S-phase entry that is in turn rescued by a cleaved-mimic 115 
BMP.   An additional, and in a broader context, significant conclusion of our 116 
quantitative studies is that the detection of serum BMP4 has previously been 117 
underestimated by up to 1000-fold due to unrecognized lack of the N-terminal 118 
epitopes of serum BMPs used for ELISA quantification. 119 
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 120 
RESULTS  121 
Potent forms of BMP4-containing dimers in serum stimulate newt myotube 122 
S-phase re-entry 123 
The application of fractionated serum samples to cultured newt myotubes 124 
results in their concentration-dependent re-entry into S-phase, quantitated as 125 
the percentage of myotubes incorporating BrdU during a 12 hours pulse (Tanaka 126 
et al., 1997). We used this quantitative myotube response to measure the amount 127 
of “S-phase Re-entry inducing Factor” (SPRF), in different fractions from serum.  128 
By quantitating activity versus total protein concentration we had previously 129 
found that SPRF activity is enriched by 20-fold over serum in commercially 130 
produced, low-purity bovine thrombin preparations and that it was possible to 131 
separate SPRF from its activator using several different chromatographic 132 
methods (Tanaka et al., 1999)(Straube et al, 2004). To molecularly identify SPRF, 133 
the thrombin preparation was subjected to four sequential steps of column 134 
chromatography (Figure S1A).  The specific activity of SPRF was measured 135 
across sequential fractions from each column and fractions containing the peak 136 
of activity were pooled and applied to the next chromatography step. “Fold 137 
purification” was calculated based on the fold increase in specific activity found 138 
in the peak pool and “yield” was calculated based on the total amount of activity 139 
found in the peak pool from each step (Figure S1A).  The most purified fraction 140 
was subjected to non-reducing SDS-PAGE. Mass spectrometry analysis of trypsin-141 
digested proteins of the gel regions between 28-39 kD identified 34 major 142 
proteins that included BMP4, BMP5, and BMP7 (Table S3).  A visual screen of 16 143 
commercially available recombinant proteins on the myotube assay suggested 144 
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that only BMP4 could induce a myotube response.  To determine if the presence 145 
of BMP4 correlated with the increased purification of SPRF, we performed 146 
western blotting after loading equal amounts of total protein from the peak pools 147 
on SDS PAGE. The starting material and peak pool from the cation exchange step 148 
showed undetectable levels of BMP4 whereas we observed a highly enriched 149 
representation of BMP4 in the last two column steps (Figure S1B). Western 150 
blotting across the last size exclusion fractionation (equal volume loading of 151 
samples) showed correlation between the BMP4 signal and the S-phase re-entry 152 
activity (Figure S1D).  BMP5, BMP6 and BMP7 were not detectable using 153 
currently available ELISA and western blot reagents, BMP2 which is in the same 154 
subfamily as BMP4 and very similar in sequence was detected in the most 155 
purified fractions although it had not been detected by MS (Figure S1C).  These 156 
results indicated that the presence of BMP4 and possibly BMP2 correlated 157 
quantitatively with the presence of SPRF activity during the purification. 158 
 159 
To determine if BMP4 accounts for at least part of the SPRF activity, we assayed 160 
recombinant bovine BMP4 homodimers (bBMP4/4) on newt myotubes but 161 
surprisingly high concentrations were required to elicit a response. Recombinant 162 
bBMP4/4 and bBMP7/7, individually or in combination stimulated 50% maximal 163 
S-phase response at 47 to 77 ng/ml (1.9 to 3.0 nM) (Figure 1A). In contrast the 164 
native bBMP4 present in the SPRF purification fractions induced 50% maximal S-165 
phase response at an apparent concentration of 0.06 ng/ml (2.4 pM) (Figure 1A). 166 
These results suggested that either native BMP4 containing dimers were 167 
intrinsically more potent than recombinantly produced proteins, or accessory 168 
factors work in parallel to or in concert with native BMPs to account for their 169 
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increased potency. To investigate this discrepancy we first assayed recombinant 170 
bBMP4/7 heterodimers. Consistent with previous reports (Israel et al., 1996) 171 
that BMP heterodimers have higher activity than homodimers, the recombinant 172 
bBMP4/7 heterodimer showed approximately 19-fold higher potency when 173 
compared with recombinant bBMP4/4 homodimer (Figure 1A, Figure S2A) but 174 
this still left a 40-fold discrepancy in activity between native BMPs in the purified 175 
SPRF material and the recombinant BMP preparations.  176 
 177 
To determine if BMPs represent a major part of the activity in the serum 178 
preparations, we added recombinant noggin-FC, a stoichiometric, pan-specific 179 
inhibitor of BMPs (Holley et al., 1996; Zimmerman et al., 1996), to both partially 180 
purified SPRF and to recombinant bBMP preparations, and found extinction of 181 
activity (Figure 1B). Noggin-Fc also inhibited the cell cycle re-entry activity 182 
present in fetal calf serum (Figure S2B). Using noggin-FC as an affinity reagent, 183 
we specifically depleted BMPs from a partially purified SPRF preparation and 184 
found depletion of activity that could be quantitatively recovered using 1% SDS 185 
as eluate (Figure 1C). The eluate was separated on non-reducing SDS-PAGE, 186 
proteins were retrieved from gel slices and recovery of bioactivity found in the 187 
size range of 28-36 kD in this eluate (Figure 1D). Mass spectrometry analysis of 188 
this gel slice identified BMP2, BMP4, BMP5, BMP6 and BMP7.  189 
 190 
We then specifically immunodepleted BMP4 from the Butyl20 fraction using 191 
polyclonal antibodies and correspondingly observed a loss of activity which 192 
could be quantitatively recovered from the immunoprecipitate (Figure 1E). This 193 
result shows that BMP4-containing homo- or heterodimers are a major and 194 
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sufficient constituent of the activity. Mass spectrometry analysis of the active 195 
region of a non-reducing gel between 28 and 36 kD identified BMP2, BMP4, 196 
BMP5, BMP6 and BMP7 (Table S1). Since no detectable cross-reaction of the 197 
anti-BMP4 antibody was observed with BMP5, BMP6 and BMP7 these results 198 
strongly suggest that the serum preparations contain BMP2/4, BMP4/5, BMP4/6 199 
and BMP4/7 heterodimers. Taken together these results show that BMP-200 
containing dimers account for the SPRF activity and are sufficient for cell cycle 201 
re-entry in newt myotubes.  202 
 203 
Activated BMPs are cleaved at multiple target sites by thrombin and 204 
plasmin 205 
Considering the large discrepancy in potency between serum-derived BMPs 206 
versus recombinant BMP4/7, and earlier observations that the serum factor is 207 
activated by thrombin and plasmin proteolysis, we investigated whether BMPs 208 
are direct targets of thrombin and plasmin. The treatment of recombinant 209 
hBMP4/7 with purified thrombin resulted in a 10-15-fold increase in activity 210 
while treatment with plasmin resulted in a 20-30-fold increase in activity (Figure 211 
2A). Plasmin and thrombin also induced increased potencies in the recombinant 212 
hBMP2/2, hBMP4/4 and hBMP7/7 (Figure 2B, Figure S2C-D).  We noticed in 213 
western blots reduced signal for protease treated BMP2, BMP4 and BMP7 214 
(Figure 2C) which could have reflected either a general proteolytic degradation 215 
of proteins or an alteration of a major epitope for antibody binding.  We 216 
therefore analyzed purified, bacterially-produced recombinant hBMP4/4 after 217 
plasmin or thrombin treatment by silver staining versus western blot.  Human 218 
BMPs were the only available preparations with sufficient purity for such 219 
  10 
detailed biochemical analysis and are practically identical in sequence to bovine 220 
BMP4 (1 amino acid substitution) so we performed the analyses in Figure 2 and 221 
subsequent work with human recombinant BMPs. Silver staining showed a 222 
progressive appearance of multiple lower molecular weight bands with 223 
increased incubation with plasmin and thrombin, but the overall protein level 224 
remained constant, excluding generalized proteolytic degradation, but rather 225 
suggesting that an alteration of the epitope responsible for antibody binding 226 
(Figure 2D).  227 
 228 
We next pursued mapping the target sites on BMP4 for thrombin and plasmin. 229 
Thrombin cleaves the peptide bond following positively charged residues with 230 
high selectivity while plasmin cleaves the peptide bond following lysine or 231 
arginine residues with relatively relaxed surrounding sequence requirements 232 
(Mattler and Bang, 1977; Ryan et al., 1976; Vindigni, 1999). The BMP4 N-233 
terminus contains multiple lysine and arginine residues, which when cleaved 234 
would cause the N-terminus to be cleaved into small fragments and released 235 
(Figure S3). This N-terminal domain has previously been characterized as a 236 
heparin-binding domain that causes BMP retention in heparin-containing gels 237 
and can be removed by plasmin treatment, which results in higher BMP2 238 
bioactivity on alkaline phosphatase induction assay (Ruppert et al., 1996; Uludag 239 
et al., 2001) (Roedel et al., 2013).  In addition BMP4 also contains lysine residues 240 
in the centrally (K78) and in the C-terminus (K99, K103) with the K103 site 241 
representing an ideal plasmin substrate sequence, conserved among BMPs . Due 242 
to intramolecular disulfide bonding, the peptides resulting from such cleavages 243 
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are predicted to remain covalently associated with the mature dimer (Figure 244 
S3E). 245 
 246 
To map the thrombin and plasmin–associated cleavage sites we employed 247 
Edman sequencing of hBMP4/4 and hBMP4/7, which detects newly generated N-248 
terminal amino acids after protein cleavage. We first analyzed hBMP4/4 to 249 
understand cleavage sites on the BMP4 polypeptide alone. The untreated sample 250 
yielded the sole presence of the classical N-terminus of the mature BMP4, SPKHH 251 
(Figure S3A, pink, Data S1, Table S2). Thrombin treated BMP4/4 revealed a 252 
single new N-terminus -ARKKNK- as (Figure S3A, green, Data S1, Table S2) 253 
indicating that thrombin targets arginine (R8) which is also consistent with gel 254 
mobility data (Figure 2D, Figure S3B). In contrast, plasmin-treated BMP4/4 255 
yielded two N-termini, KKNKN, and NYQEM indicating that plasmin targets R10 256 
and K103 (Figure S3A, orange, Data S1, Table S2) consistent with gel mobility 257 
data showing the appearance of two major lower molecular weight peptides 258 
(Figure S3B). These findings suggest that the increased potency of plasmin-259 
treated BMPs derives from the additional cleavage at K103 (Figure S3A , Data S1, 260 
Table S2). 261 
 262 
To confirm the C-terminal plasmin site, we also performed mass spectrometry 263 
and compared the presence of peptides in preparations that had or had not been 264 
reduced and alkylated (to break disulfide bridges and prevent their re-265 
formation). The C-terminal peptides NYQEMVVEGCGCR and some traces of 266 
VVLKNYQEMVVEGCGCR were the major peptides detected in the plasmin-267 
treated samples that had been reduced and alkylated but were not present in the 268 
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non-reduced samples. This result confirms the occurrence of plasmin-mediated 269 
cleavage at the C-terminal K99 and/or K103 residues and retention in the native 270 
dimer via disulfide bonds.  271 
 272 
Since we had observed a high shift in potency of plasmin-cleaved BMP4/7 273 
(Figure 2A, Figure S3C), we performed Edman sequencing of the plasmin derived 274 
non-reduced recombinant human BMP4/7 to determine cleavage sites in BMP7. 275 
The analysis yielded the BMP4 sequences -NYQEM- and -KKNKN as well as three 276 
BMP7 sequences, DLGWQDW, MANVAEN, NMVVRAC, indicating cleavage of 277 
BMP7 in several internal locations (Figure S3A, Data S1, Table S2).  These results 278 
show that BMP4 and BMP7 have plasmin cleavage sites beyond the previously 279 
known N-terminal K8 sequence on BMP2 (Roedel et al., 2013; Uludag et al., 280 
2001). Cleavage at these sites maintains an intact BMP molecule in the disulfide 281 
bonded state, and correlates with the increased ability of plasmin to activate the 282 
BMP4/7 heterodimer. 283 
 284 
In vivo cell cycle entry of dedifferentiating muscle involves SMAD-mediated 285 
BMP signaling and is protease-sensitive 286 
To test the role of BMP signaling in S-phase entry of skeletal muscle cells in vivo, 287 
we sought to autonomously block BMP signaling in newt skeletal muscle fibers 288 
by expression of dominant negative BMP receptors (dnBMPR). To validate the 289 
dnBMPRs, we first transfected myotubes in vitro with dnAlkLK2, dnAlkLK3 and 290 
dnAlkLK6 expression constructs together with a nucGfpFP construct and then 291 
challenged them 24 hours after plating with recombinant hBMP4/7. In control 292 
samples transfected with nucGfpFP only, S-phase response in GFP+ myotubes 293 
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was 24±4%. In contrast all tested dnBMPR including dnAlkLK2, dnAlk3 and 294 
dnAlkLK6 yielded strong suppression of the S-phase response to 2.0 ± 1.8% (p = 295 
2.26 x 10-08), 6.5 ± 4.6% (p = 7.12 x 10-09) and 0.2 ± 0.6% (p = 7.47 x 10-08) 296 
respectively (Figure 3A). These results indicate that blockage of BMP signaling 297 
within the myotube is sufficient to block the S-phase response.  298 
 299 
To block signaling in vivo, we specifically expressed DNA constructs in newt 300 
skeletal muscle fibers via the co-electroporation of a muscle-specific MCK:cre, a 301 
loxP expression cassette CAGGs: loxP-Cherry 3PA-loxP-Histone2B-YFP  or CAGGs: 302 
loxP-Cherry 3PA-loxP-Histone2B-YFP-T2A-dnALK flanked by Tol2 transposon 303 
sites, and a Tol2 transposase expression plasmid (Sandoval-Guzman et al., 2014). 304 
This procedure yields expression of the H2B-YFP and dnALKs specifically in 305 
MHC+ muscle fibers of the intact limb. Upon limb amputation, muscle fibers 306 
cellularize prior to S-phase entry yielding YFP+/MHC- proliferating cells in the 307 
regeneration blastema as assessed by PCNA staining and by incorporation of 308 
nucleotide analogues (Sandoval-Guzman et al., 2014). To assay DNA synthesis in 309 
cells deriving from labeled fibers, electroporated limbs were injected daily with 310 
EdU 8-13 days post-limb amputation prior to harvesting (Figure 3B). In control 311 
limbs expressing H2B-YFP alone, 67.2±6.8% of muscle derived YFP+MHC- cells in 312 
the blastema had incorporated EdU (Figure 3C-E). In contrast, expression of 313 
dnALK2, dnALK3 or dnALK6 with H2B-YFP yielded a lower EdU labeling index of 314 
47 ± 7.6% (p = 0.1106), 41 ± 8.4%(p = 0.0522), 43.2 ± 6.2% (p = 0.042), 315 
respectively, indicating the participation of BMP signaling during S-phase of 316 
skeletal muscle derived cells (Figure 3E).   These results indicated that BMP 317 
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signaling is acting to promote cell cycle re-entry in vivo in dedifferentiating 318 
muscle cells. 319 
 320 
To determine whether the BMP signaling proceeded via intracellular SMAD 321 
activity we used a SMAD-luciferase reporter (Collery and Link, 2011; 322 
Korchynskyi and ten Dijke, 2002). Cultured newt myotubes transfected with the 323 
reporter displayed a BMP4/7-dependent induction of luciferase activity.  This 324 
response was blocked by provision of the BMP-inhibitor, noggin, indicating that 325 
the newt myotube response to BMP activates SMAD signaling (Figure 4A).  326 
Transfection of this reporter in vivo into the limb blastema also showed 327 
increased reporter activity during the stage of muscle dedifferentiation, at 6 and 328 
12 days post-amputation (Figure 4B).  The limb blastema consists of cells 329 
deriving from different tissues.  To directly determine if SMAD signaling takes 330 
place in dedifferentiating muscle cells, we labeled muscle fibers with H2B-YFP 331 
via electroporation as described above and performed immunofluorescence 332 
staining for nuclear pSMAD1/5/8 staining.  As shown in Figure 4C, YFP+ cells 333 
showed nuclear pSMAD1/5/8 staining confirming the implementation of SMAD 334 
activity during muscle dedifferentiation. 335 
 336 
We next aimed to examine the relevance of BMP protease activation to in vivo 337 
muscle cell cycle re-entry.  We first assessed in vitro the relative effectiveness of 338 
recombinantly produced WT BMP to a mutant BMP lacking the N-terminus (ΔN-339 
BMP4) that mimics the N-terminally cleaved form by assaying identically 340 
produced proteins in the linear range on myotubes.   Volume for volume the ΔN-341 
BMP4 more potently  induced cell cycle re-entry than the full-length protein 342 
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(Figure 4D).  Mutations in the C-terminal site prevented efficient production of 343 
secreted BMP and therefore, this C-terminal cleavage could not be analysed by 344 
mutational analysis (data not shown).   345 
 346 
We then compared the in vivo effectiveness of the WT and  ΔN forms to 347 
accelerate dedifferentating myofiber cell cycle entry by overexpressing the BMPs 348 
in the early blastema and then assaying the proliferation of muscle cell progeny 349 
by MCM2 staining at 13 dpa. Injection of equal amounts of baculovirus for the 350 
two constructs showed a higher proliferation index of dedifferentiating muscle-351 
derived cells in samples expressing ΔN-BMP4 compared to the full length BMP4 352 
(Figure 4F,G).   Finally we asked if inhibition of serine proteases in the 353 
amputated limb reduced cell cycle entry of muscle-derived cells upstream of 354 
BMP.  Injection of YFP-muscle-labeled limbs with AEBSF, an irreversible 355 
inhibitor of both thrombin and plasmin (Powers et al., 2002), depressed EdU 356 
incorporation in YFP+ muscle fiber-derived cells compared to PBS-injected limbs 357 
(Figure S4A,B).  Expression of the ΔN-BMP4  restored EdU incorporation in YFP+ 358 
muscle fiber-derived cells showing that serine protease activity acts upstream of 359 
cleaved-BMP-dependent muscle cell cycle re-entry (Figure S4C). This epistasis 360 
analysis confirms a role for protease activity as a positive, upstream regulator of 361 
BMP-driven induction of the cell cycle during limb regeneration.  362 
 363 
DISCUSSION 364 
Here we identify BMPs as serum factors that can stimulate cell cycle entry of 365 
differentiated newt skeletal myotubes and muscle fibers, a key step in muscle 366 
dedifferentiation during limb regeneration.  We further show that BMP activity is 367 
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potentiated by cleavage mediated by thrombin and plasmin.  These observations 368 
lead to a model in which resting skeletal muscle fibers in the intact limb remain 369 
sequestered from plasma BMPs that are circulating within intact blood vessels. 370 
Limb amputation damages the endothelium that leaks plasma BMPs into 371 
surrounding tissues and initiates the clotting cascade triggering not only fibrin 372 
clot formation, but also proteolytic processing of BMPs. The progeny of the 373 
damaged muscle fibers are exposed to and respond to these activated BMPs with 374 
cell cycle re-entry.  375 
 376 
The expression of BMP4 is also upregulated early after limb amputation in 377 
Xenopus and Axolotl which would also be a target of activating proteolysis, 378 
further reinforcing BMP action during early regeneration (Beck et al., 2006; 379 
Guimond et al., 2010; Knapp et al., 2013) (Kochegarov et al., 2015).  Another 380 
potential BMP source is peripheral nerves, as BMP2 and BMP7 were shown to 381 
substitute a proregenerative role of nerves in the accessory limb model and are 382 
expressed in DRG neurons (Makanae et al., 2014).  Two inhibition studies 383 
implicated BMP signaling in early steps of limb regeneration, but since inhibition 384 
of the pathway had been elicited by global expression of noggin, it was unclear if 385 
the negative effects on cell proliferation had been through a direct or indirect 386 
means (Beck et al., 2006; Guimond et al., 2010; Knapp et al., 2013). Here. through 387 
cell autonomous inhibition of BMP signaling, we show a direct effect of the 388 
pathway on muscle-derived cell cycle entry.  This pathway appears to be 389 
working in parallel to the recently described MLP pathway (Sugiura et al., 2016) 390 
which would explain the partial loss of EdU incorporation when we blocked BMP 391 
signaling in in vivo muscle fibers, while we observed complete block of S-phase 392 
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in response to serum in the in vitro assay system, where MLP was not present in 393 
the culture. 394 
 395 
In other biological systems, recombinant BMP4/4 had been used to implicate 396 
BMP4/4 as a potential bioactive serum factor that could support mouse ES cell 397 
pluripotency and the conversion of oligodendrocyte precursors into a neural 398 
stem-like cell, but a paradox existed in which the concentrations of recombinant 399 
BMPs required for cell stimulation did not match the very low concentrations of 400 
BMPs measured in serum (Kondo and Raff, 2000; Ying et al., 2003) (Park et al., 401 
2008; Tacke et al., 2007; Wendling et al., 2007).  Therefore it was unclear 402 
whether other serum factors were really required. Our biochemical approach 403 
provides an explanation that could resolve this controversy. First we show that 404 
in our in vitro assay, serum BMPs quantitatively account for the activity. Our 405 
work also strongly suggests that a significant fraction of the BMP4 in serum is 406 
complexed to BMP5, 6 and 7 as heterodimers. This is important considering that 407 
BMP4/7 is more potent than BMP4/4 in our and other cellular assays. Next our 408 
work indicates that the quantification of serum BMPs by western blot or ELISA 409 
vastly underestimates the concentration of BMPs in serum. ELISAs used to 410 
quantitate BMP4 and BMP7 employ antibodies that are directed against the N-411 
terminus. Our work shows that since the N-terminus is lacking in serum BMPs, 412 
the vast majority of BMPs present in serum are likely not detected. Using ELISA 413 
kits, the serum concentration of BMP4 has been estimated at 0.04 ng/ml and 414 
BMP7 at 0.01-0.28 ng/ml (Park et al., 2008; Tacke et al., 2007; Wendling et al., 415 
2007). Based on our measurements of the loss of immunoreactivity in western 416 
blots using a commercial polyclonal anti-BMP antibody, and the enrichment of 417 
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BMP activity along the different steps of purification, we calculate that BMP4 is 418 
present in serum at a concentration of 20-100 ng/ml, which is 1000-fold higher 419 
than previous estimations. Significantly, the re-estimated concentration of this 420 
molecule is at levels highly relevant to cellular assays. 421 
 422 
In summary, our work provides insight into how a local injury initiates activation 423 
of the BMP signaling pathway and how this signaling pathway acts directly on a 424 
cellular mechanism involved in generating blastema cells from mature tissue, 425 
namely cell cycle entry during dedifferentiation of muscle fibers. This molecular 426 
insight has important implications for promoting a proliferative state for the 427 
purpose of regeneration. 428 
 429 
EXPERIMENTAL PROCEDURES 430 
See STAR methods page. 431 
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FIGURE LEGENDS 573 
Fig. 1. BMP4 containing dimers are necessary and sufficient for S-phase re-574 
entry, but recombinant molecules are less potent than native BMP4s. 575 
(A) Dose response curves for recombinant bovine BMP4/4, BMP7/7 and 576 
BMP4/7.  Square, green: Serum-derived BMP4 (SPRF); diamond, pink: 577 
recombinant BMP4/7; triangle, blue: recBMP4/4; inverted triangle, red: 578 
recBMP7/7; circle, lilac:  mixture of recBMP4/4 plus recBMP7/7. Data are 579 
presented as mean  SEM (n = 3). 580 
(B) Addition of Noggin-FC to BMPs or SPRF inhibits S-phase. Square, green: 581 
Serum-derived BMP4 (SPRF); circle, pink: recombinant BMP4/7 heterodimer. 582 
Data are presented as mean  SEM (n = 3). 583 
(C) Noggin-FC-mediated depletion of BMPs and recovery from eluate. SPRF was 584 
pre-incubated with ProteinG beads (SPRF, PrG bead dep.) then incubated with 585 
noggin-FC-linked beads (SPRF, noggin-FC + PrG bead dep.). Elution from bound 586 
beads in 1% SDS (noggin-FC eluate) results in recovery of activity. Data are 587 
presented as mean  SEM (n = 9). Significance calculated by Student’s t-test. 588 
(D) Sample eluted from the noggin-FC precipitate using 1% SDS (noggin-FC 589 
eluate) was separated on non-reducing SDS-PAGE and protein recovered by 590 
electroelution from gel slices as indicated. Positive activity in bioassay is 591 
observed in the gel slice in the size range of 28-36 kD (gel slice 7). Data are 592 
presented as mean  SEM (n = 3). 593 
(E) Immunodepletion of BMP4 from serum fraction depletes activity and elution 594 
recovers activity. SPRF was first pre-incubated with ProteinG beads (SPRF, PrG 595 
bead dep.) then incubated with anti-BMP4 antibody-linked beads for 596 
immunodepletion (SPRF, αBMP4 + PrG bead dep.). Elution from bound beads at 597 
pH11.5 (αBMP4 eluate) results in recovery of activity. Data are presented as 598 
mean  SEM (n = 9) (SPRF, PrG bead dep. and SPRF, αBMP4 + PrG bead dep.) and 599 
n = 54 (αBMP4 eluate)). (see also Table S1) 600 
 601 
Fig. 2. Increased potency of recombinant BMP4/7 after thrombin and 602 
plasmin treatment. 603 
(A) Dose response of untreated recombinant human BMP4/7 (circle, green, solid 604 
line) and after treatment with thrombin (inverted triangle, blue, dotted line) or 605 
plasmin (square, red, dashed line). Data are presented as mean  SEM (n = 3). 606 
(B) Plasmin enhances the potency of human BMPs. Recombinant hBMP2/2 607 
(circle, green line), BMP4/4 (square, purple line) or BMP7/7 (triangle, pink line) 608 
were incubated with increasing levels of plasmin. Samples were assayed on newt 609 
myotubes. Data are presented as mean  SEM (n = 3). 610 
(C) Western blot analysis of hBMP samples before and after plasmin treatment. 611 
Lanes 1-4: rhBMP2: 0.48 ng, 0.24 ng, 0.12 ng, 0.06 ng; rhBMP4 and rhBMP7: 612 
0.96ng, 0.48 ng, 0.24 ng, 0.12 ng 613 
(D) Treatment of hBMP4/4 homodimer with plasmin and thrombin results in 614 
altered gel mobility on silver stained SDS-PAGE and loss of immunoreactivity in 615 
western blot. Thrombin treatment results in a single smaller BMP4 band. 616 
Treatment with plasmin yields multiple cleavages. Time in hours refers to time 617 
of incubation with protease. (see also Figure S2C-D). 618 
 619 
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Fig. 3. Inhibition of BMP signaling via expression of dominant negative BMP 620 
receptors inhibits cell cycle re-entry in vitro and in vivo. 621 
(A) Cultured newt myotubes electroporated with expression plasmids for the 622 
three dominant negative BMP receptors (dnALK2, dnALK3, dnALK6) together 623 
with nucGFP or nucGFP alone as control were stimulated with recombinant 624 
hBMP4/7 and then assayed for BrdU incorporation. Data are presented as mean 625 
 SEM (n = 9 and n = 15 in control and dnBMPR respectively). Significance 626 
calculated by Student’s t-test. 627 
(B) Schematic outline of the in vivo experiments. Dotted lines indicate the cross 628 
sections for immunostaining. Representative staining pictures from a dnALK6 629 
overexpressed limb are shown in (C) and (D).  630 
(C) YFP+ nuclei are MHC+ and EdU- in the stump muscle. 631 
(D) Dedifferentiated YFP+ nuclei in the blastema lose MHC and a fraction 632 
incorporates EdU. Arrows point to YFP+EdU- cells. Arrowheads point to 633 
YFP+EdU+ cells.  634 
(E) Overexpression of dnALKs in myofibers reduces the cell cycle entry of the 635 
dedifferentiated cells during limb regeneration. Data are presented as mean ± 636 
SEM (n = 4). Significance calculated by Student’s t-test. 637 
 638 
Fig. 4.  Molecular analysis of BMP signaling events in vitro and in vivo 639 
(A) Luciferase activity assay of Smad-reporter in A1 newt myotube cultures. Data 640 
are presented as mean ± SEM (n=8). Significance calculated by Student’s t-test. 641 
(B) Luciferase reporter assay indicates increased SMAD signaling in vivo during 642 
the dedifferentiation stage of limb regeneration. The Smad-reporter and the 643 
Renilla luciferase control plasmids were electroporated into the uninjured newt 644 
limb, 5dpa and 11dpa blastemas. The luciferase activity was analyzed the next 645 
day. Data are presented as mean ± SEM (n=5). Significance calculated by 646 
Student’s t-test. 647 
(C) Dedifferentiating muscle cells display nuclearly localized phosphoSMAD.  648 
Immunohistochemical detection of increased phospho-smad1/5/8 in blastema 649 
nuclei compared to the stump (top of left panel). White line marks the 650 
amputation plane. Arrow indicates the stump region with low level of pSMAD. 651 
Asterisk indicates the background fluorescence of the myofibers.  652 
Inset (right) de-differentiating YFP-expressing myofibre progeny (green) have 653 
pSMAD+ nuclei (red). Arrowheads,YFP+pSMAD+ cells in the blastema. Scale bars, 654 
200 μm (overview) and 20 μm (insert). 655 
(D) Recombinant ΔN-BMP4 is more potent in inducing cell cycle reentry in 656 
cultured myotubes compared to full-length BMP4. FCS treatment was used as a 657 
positive control. Data are presented as mean ± SEM (n = 3 in control and 6 in all 658 
the other treatments). Significance calculated by Student’s t-test. 659 
(E) Schematic representation of the experiment testing the potency of the ΔN-660 
BMP4 during limb regeneration. Equal amounts of baculovirus expressing full 661 
length BMP4, ΔN-BMP4 or cherry was injected into the early blastema. Muscle 662 
cell proliferation was quantified by MCM2 staining in the YFP+ myofibre progeny 663 
at 13 dpa. 664 
(F) Dedifferentiated YFP+ nuclei in the blastema proliferate. Arrows point to 665 
YFP+MCM2- cells. Arrowheads point to YFP+MCM2+ cells.  666 
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(G) Both full length BMP4 and ΔN-BMP4 increase the fraction of proliferating 667 
myofibre derived cells but ΔN-BMP4 is more potent compared to full-length 668 
BMP4. Data are presented as mean ± SEM (n = 8). Significance calculated by 669 
Student’s t-test. 670 
 671 
 672 
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 682 
EXPERIMENTAL PROCEDURES 683 
CONTACT FOR REAGENT AND RESOURCE SHARING: 684 
Further information and requests for resources and reagents should be directed 685 
to and will be fulfilled by the Lead Contact, Elly Tanaka (elly.tanaka@imp.ac.at) 686 
 687 
EXPERIMENTAL MODEL AND SUBJECT DETAILS: 688 
Red-spotted newts, Notophthalmus viridescens, were supplied by Charles D. 689 
Sullivan Co. (Nashville, TN, USA). Animals were kept in tanks fill with tap water 690 
at density of 4 animals/0.01m2 and kept at 18-20°C with regular water change. 691 
Aquaria contained environmental enrichments composed of ceramic pieces for 692 
hiding and artificial plants. Animals were fed with frozen blood worms. Unsexed 693 
animals were randomly assigned to experimental groups.  694 
Cell line, from Notophthalmus viridescens, called the A1 cell line was passaged 695 
and differentiated as described in Tanaka et al 1997.  Newt myoblasts were 696 
cultured in 62.5% MEM (Invitrogen), 10% fetal bovine serum (Perbio), 697 
penicillin/streptomycin (Gibco) and glutamine (Gibco) on gelatin (Sigma) coated 698 
dishes, at 25°C and 2% CO2. Cells were trypsinized once per week and split 1:3 699 
before plating on flasks (Corning or Nunc) coated with 0.75% porcine gelatin Sex 700 
unknown.  Cells not authenticated. 701 
Human HEK293 cell line:  Shaking cultures were maintained at 37°C, 8% CO2 in 702 
Freestyle293 serum-free medium (Thermo Fischer).  Sex:  female.  Cells 703 
purchased and not further validated in the laboratory.   704 
Sf9 Cell line for baculovirus production:  We used expresSF+ Cells 705 
(ProteinSciences (Meriden, CT, USA), sex: unknown.  BV recombinants were 706 
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generated upon co-transfection of linearized bacmid DNA and a rescue vector 707 
using expresSF+ cell line (Protein Sciences Corp.). Cultured cells were 708 
maintained under continuous rotation suspension culture at 25˚C in ESF 921 709 
Insect Cell Culture Medium (96-001, Expression Systems). Virions were 710 
subjected to two rounds of amplification previous to a final expansion, where 711 
500 ml of expresSF+ cells at 0.6x10^6 cells/ml were infected with 500 µl of BV 712 
virion-containing supernatant. This final incubation proceeded for 4 days at 25˚C 713 
under continuous rotation, after which baculovirus particles were concentrated 714 
and purified using a gradient separation method. 715 
 716 
METHOD DETAILS 717 
Purification/Chromatography.  718 
Crude bovine thrombin (Celliance Corp) was reconstituted at 20 mg/ml in 20 719 
mM cation buffer (6.6 mM HEPES, 6.6 mM MES, 6.6 mM NaAcetate (pH 6.5) and 720 
loaded onto a HiTrap CMFF column. The flow through was collected and 721 
remaining thrombin inhibited with D-Phe-Pro-Arg-chloromethylketone, HCL 722 
(PPACK, Calbiochem). The flow through was mixed with phosphate buffer (pH 723 
7.0) and ammonium sulfate to a final concentration of 33.3 mM and 100 mM 724 
respectively and loaded onto a HiTrap ButylFF column. Bound proteins were 725 
eluted in 50 mM phosphate buffer pH 7.0 by a stepwise gradient of 10 CV 100 726 
mM ammonium sulfate, 0 mM ammonium sulfate, 20% Ethanol and 40% 727 
Ethanol. 728 
The fraction eluted at 20% Ethanol (Butyl20) was mixed with NaCl to a final 729 
concentration of 200 mM and loaded onto a HiTrap Heparin column. Bound 730 
protein was eluted with a linear gradient of NaCl (0 mM to 1000 mM). Fractions 731 
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eluted between 430 mM and 680 mM NaCl were pooled, concentrated by 732 
ultrafiltration (MWCO 30,000) and mixed with CAPS (pH 11) to a final 733 
concentration of 100 mM. After incubation at room temperature for 4 hours the 734 
material was applied to a Superdex 200 column and fractions were collected. 735 
Immunoprecipitation.  736 
As a starting point for the immunoprecipitation a fraction of an intermediate step 737 
of the purification was used (Butyl20). Butyl20 was concentrated and dialyzed 738 
into 1X PBS. In order to remove IgG, the material was incubated with ProteinG 739 
beads at room temperature for 1 hour. Beads were removed and Butyl20-∆IgG 740 
was incubated at 4°C, overnight with a) Noggin-FC or b) anti-BMP4 antibody 741 
(goat, polyclonal, R&D) or c) anti-EGFP antibody (goat, polyclonal, P.E.P.) that 742 
had been linked covalently to ProteinG beads. The beads were harvested and 743 
washed with a) 1X PBS, 0.01% SDS or b)/c) 10 mM phosphate buffer (pH8). 744 
Bound proteins were eluted with a) a step gradient of 0.1% SDS, 0.5% SDS, 1% 745 
SDS in 1X PBS or b)/c) 100 mM Phosphate buffer (pH11.5), 10 µg/ml aprotinin, 746 
for neutralization phosphate buffer (pH6.8) was added to a final concentration of 747 
100 mM 748 
Preparative SDS-PAGE.  749 
The concentrated eluate that was obtained from immunoprecipitation was mixed 750 
with 5X sample buffer w/o DTT, incubated at 37°C for 1 hour and loaded onto a 751 
4%-20% Tris-Glycine gradient gel (Anamed). Eletrophoresis was carried out at 752 
room temperature and 100 V in 1X SDS running buffer. Single gel slices were 753 
obtained and proteins were eluted using D-Tube dialyzer midi (Novagen). 754 
Elution was carried out in a horizontal electrophoresis chamber at room 755 
temperature, 100 V for 7 hours. 756 
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SDS-PAGE and western Blots.  757 
Samples were mixed with 5X Sample Buffer (with or without DTT), incubated at 758 
95°C for 5 min and loaded either onto 4%-20% Tris-Gycine gels (Anamed) or 759 
12% Bis-Tris gels (NuPAGE). Electrophoresis was carried out either in 1X SDS 760 
running buffer or 1X MES-SDS running buffer (NuPAGE) at room temperature 761 
and 130 V. After blotting the membrane was blocked with 1X PBS, 2% BSA. 762 
Antibodies for western blot were reconstituted according to manufacture’s 763 
advice and used at the following dilutions: BMP2 (rabbit, polyclonal, Acris 764 
antibodies) 1:1000, BMP4 (goat, polyclonal, R&D) 1:5000, BMP4 (goat, 765 
polyclonal, Santa Cruz) 1:1000, BMP5 (goat, polyclonal, R&D) 1:1000, BMP6 766 
(goat, polyclonal, R&D) 1:1000, BMP7 (rabbit, polyclonal, Prepro Tech EC Ltd) 767 
1:5000. As standards for western blot commercially available recombinant BMPs 768 
(R&D) were used. 769 
De-glycosylation of samples.  770 
Samples were denatured by adding SDS and DTT at a final concentration of 0.5 % 771 
and 20 mM respectively and subsequent heating to 95°C for 5 min. In the case of 772 
subsequent activity analyses the denaturing procedure was performed in the 773 
absence of DTT, at 37°C for 2 hours. After cooling to room temperature NP40 774 
was added to a final concentration of 1%. The sample was mixed and 10X assay 775 
buffer (500 mM sodium phosphate, pH 7.5) was added to achieve a final 776 
concentration of 1X. The sample was then incubated with N-Glycosidase F 777 
(PNGase F) at a final concentration of 1200 U/ml (0.36 mg/ml) for 1 hour at 778 
37°C. 779 
Cell culture.  780 
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Newt myoblasts were cultured in 62.5% MEM (Invitrogen), 10% fetal bovine 781 
serum (Perbio), penicillin/streptomycin (Gibco) and glutamine (Gibco) on 782 
gelatine (Sigma) coated dishes, at 25°C and 2% CO2. In order to induce myotube 783 
formation, cells were placed into 0.5% serum medium for 5 to 6 days. Myotubes 784 
were purified by sieving the trypsinized cell preparation through a 100 micron 785 
mesh to remove large aggregates, then the flow-through was passed through a 786 
35 micron mesh, which passed the contaminating mononucleates through but 787 
trapped the myotubes.  The myotubes were washed off of the sieves and plated 788 
in 0.5% serum media on fibronectin coated 96-well plates (Tanaka, 1997). 789 
Protein fractions usually in the presence of 0.5% serum medium were added to 790 
cells 8 hours after cell preparation. Four days after adding of samples, cells were 791 
labeled with bromodeoxyuridine (BrdU, Sigma) at a final concentration of 13 792 
ug/ml. After 12 hours of labeling, cells were fixed and stained for BrDU as well as 793 
the muscle marker myosin heavy chain (MHC) as described previously (Tanaka 794 
et al., 1999). The percentage of MHC+/BrdU+ myotubes out of total MHC+ 795 
myotubes was determined using an Axioplan 2 imaging microscope (ZEISS). The 796 
specific activity of SPRF was defined in Units where the amount of material 797 
added to myotubes that resulted in a 1% BrdU+ myotube response in 150 µl of 798 
culture media. In other words, if we added an amount of serum preparation of 10 799 
µg protein /150 µl media that induced 10% of myotubes to take up BrdU, we 800 
defined this as 1U SPRF/1µg protein added. 801 
Electroporation of newt myotubes.  802 
Newt myotubes from one cell culture dish (100 mm diameter) were harvested as 803 
previously described (Tanaka et al., 1997). Cells were centrifuged (300 g, 3 min). 804 
The cell pellet was re-suspended in 300 μl ice-cold 1X Steinberg’s buffer and 805 
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transferred into a BTX electroporation device (pre-cooled to 4°C). 10 ug DNA 806 
were added per sample. The electroporation was carried out using a square 807 
pulse electroporator (BTX 830 Squarporator) at 75 V, 35 msec, for five pulses. 808 
0.5% serum medium was added, myotubes were purified as described (Tanaka 809 
et al., 1997) and plated on fibronectin coated 96-well plates.  810 
Cloning of BMP and noggin-FC constructs.  811 
Complete human cDNAs for human BMP4, human BMP7 and human Noggin were 812 
obtained from the German Resource Center for Genome Research (RZPD). The 813 
coding sequence of noggin was inserted into pSUPER-M1, a derivative of Signal 814 
pIG-plus (R&D Systems) and p23 (a kind gift from Barbara Borgonovo) to 815 
generate a CMV promoter driven construct expressing a C-terminal human IgG1 816 
Fc domain fusion. Human BMP4 and BMP7 were sub-cloned into pCMV-M2, a 817 
derivative of pCMVSport6 (Invitrogen). The bovine orthologs of human BMP4 818 
and BMP7, human BMP4_S298P and human BMP7_S295G_M315V, as well as the 819 
human ∆N-BMP4 muntant (lacking residues K3 to K14 of mature human BMP4) 820 
were generated by site-directed mutagenesis using an overlap PCR protocol.  All 821 
constructs were verified by sequencing.  822 
Cloning of dnAlk constructs. 823 
Mutations for Alk2, 3, 6: dnAlk2 K235R, dnAlk3 K261R, dnAlk6 K231R. 824 
Human Alk2, 3, 6 cDNAs were obtained from RZPD (now CellBioSource) and 825 
coding sequences were PCR amplified to incorporate point mutants by standard 826 
methods. PCR products were digested with NheI & EcoRI and ligated, 827 
transformed in DH5alpha.  A Caggs-GFP vector was digested with NheI & EcoRI 828 
and dnAlk sequences were inserted by ligation. 829 
Generation of the SceI-mTol2-Caggs-lpCherry-H2B-YFP-T2A-dnAlk constructs. 830 
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The control plasmid (SceI-mTol2-Caggs-lpCherry-H2B-YFP-T2A-User) used in 831 
((Sandoval-Guzman et al., 2014) were digested with BbvCI. 832 
Each dnAlk fragment was PCR amplified using Caggs-dnAlks for template and 833 
assembled by Gibson assembly (NEB). 834 
nucGFP was obtained from Clontech (eGFP-N2). 835 
Expression of recombinant proteins 836 
Recombinant proteins were expressed by transient transfection of suspension 837 
cultures of HEK293 cells and secreted into the medium. For the expression of 838 
BMP heterodimers expression constructs encoding the individual BMPs were co-839 
transfected into HEK293 cells. Shaking cultures were maintained at 37°C, 8% 840 
CO2 in Freestyle293 serum-free medium (Invitrogen). For transfection, plasmid 841 
DNA:PEI complexes, preformed at 10 µg/mL DNA and 100 µg/mL PEI 842 
(Polysciences, linear 25kD, #23966) in 150 mM NaCl were diluted 1:10 into cells 843 
adjusted to 2 x 106/ml. After shaking incubation for 4 hours, the medium was 844 
replaced and the cultures diluted to 1 x 106 cells/ml. After shaking for 4 days, 845 
conditioned medium was harvested by centrifugation (500 x g, 5 min), sterile 846 
filtered (0.2 µM), concentrated using Amicon Ultra-15 centrifugal filter units 847 
(Millipore), and dialyzed into PBS. Bacterially expressed recombinant human 848 
BMP4/4 used for mass spectrometry analysis was a kind gift from Walter Sebald. 849 
Bacterially expressed recombinant human BMP4/4 and BMP4/7 used for Edman 850 
sequencing were purchased from R&D. 851 
BMP Inhibition.  852 
The sample was mixed with noggin-FC or antibody and incubated at room 853 
temperature for 1 hour before loading on myotubes. 854 
Plasmin/Thrombin Digest.  855 
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If not stated differently the digests for cell assay samples was performed in 50 856 
mM Tris, 150 mM NaCl, pH7.4 (plasmin) or 50 mM Tris, 150 mM NaCl pH8.3 857 
(thrombin) buffer. Plasmin (Enzyme Research Labs) or thrombin (Enzyme 858 
Research Labs) were added to the sample at 16 ug/ml final concentration (molar 859 
ratio protease:BMP = 1:10) and incubated at 37°C for 4 hours. In order to inhibit 860 
proteolytic activity after incubation, PPACK was added to a final concentration of 861 
4 µg/ml. As a quality control, before usage, the activity and specificity of plasmin 862 
and thrombin was shown by digesting their specific substrates, ChromozymPL 863 
and ChromozymTH (Boehringer-Mannheim) respectively. Plasmin digestion of 864 
bacterially expressed recombinant hBMP4/4 for mass spectrometry analysis was 865 
performed in 20 mM ammonium carbonate, 4 mM Hepes, 4 mM NaAcetate at 866 
37°C for 15 minutes, 3 hours and 24 hours with a molar ratio of plasmin:BMP4/4 867 
of 1:60.  868 
Mass spectrometry.  869 
Gel separated proteins were reduced, alkylated and in-gel digested with trypsin 870 
as described in (Shevchenko et al., 2006). After digestion, peptides were twice 871 
extracted with 50 μl of 5% formic acid and 50% acetonitrile, dried down, re-872 
dissolved in 20 µL of 5 % (v/v) formic acid and analyzed by mass spectrometry. 873 
LC-MS/MS analysis of peptide mixtures was carried out on an Ultimate nanoLC 874 
system (Dionex, Amsterdam, The Netherlands) interfaced on-line to a LTQ linear 875 
trap mass spectrometer (Thermo Fisher Scientific, San Jose) (Waridel et al., 876 
2007). Acquired MS/MS spectra were searched against a comprehensive NCBI 877 
protein sequences database using MASCOT software (Matrix Science, v.2.2.0) 878 
installed on a local server under the following settings: mass tolerance was set as 879 
2 Da for peptide masses and 0.5 Da for masses of peptide fragments; variable 880 
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modifications: Propionamide (C), Carbamidomethyl (C), N-acetylation (Protein 881 
N-terminus), Oxidation (M); enzyme: trypsin; two missed cleavages were 882 
allowed. All hits with peptide ions scores above 25 were manually evaluated.  883 
MS analysis of plasmin treated bacterially produced recombinant 884 
hBMP4/4.  885 
Plasmin digestion was performed in 10 mM Ammonium bicarbonate. One aliquot 886 
of the sample (5 μl) was acidified (1 μl 30% formic acid) and after addition of 20 887 
μl of 80% acetonitrile solvent was evaporated in a speed vac (non-reduced 888 
sample). A second aliquot of the sample (5 μl) was acidified (1 μl 30% formic 889 
acid) to stop digestion, neutralized with ammonium bicarbonate and reduced 890 
with 10 mM DTT (2 hours at 37°C) and alkylated with 50 mM iodacetamide (1.5 891 
hours at room temperature in the dark). Excess of iodacetamide was captured by 892 
a second addition of 10 mM DTT and further incubation for 1 hour at room 893 
temperature. After addition of 20 μl of 80% acetonitrile solvent was evaporated 894 
in a speed vac and dry samples were stored at -20°C until analysis. For HPLC-895 
MS/MS analysis samples were separated in a linear gradient of 896 
water/acetonitrile with 0.1% formic acid on a 75 μm i.d. C-18 Acclaim capillary 897 
column (Dionex, Idstein, Germany) at a flow rate of 200 nl/min with an Eksigent 898 
2D Nano-LC system (Eksigent, Dublin, CA, USA). The HPLC system was 899 
hyphenated via a TriVersa Nanomate automatic source (Advion, Ithaca, USA) to 900 
an Orbitrap-Velos mass spectrometer (Thermo Fisher Scientific, Bremen, 901 
Germany) operated in data-dependent acquisition mode with a nominal 902 
resolution of 60000 at 400 m/z and lock mass enabled for MS spectra and 903 
MS/MS acquisition in the Velos ion trap. 904 
Animal procedures 905 
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Red-spotted newts, Notophthalmus viridescens, were supplied by Charles D. 906 
Sullivan Co. (Nashville, TN, USA). Plasmid preparation injection, and 907 
electroporation were carried out as in (Sandoval-Guzman et al., 2014). Animals 908 
were anesthetized in 0.1% ethyl 3-aminobenzoate methanesulfonate (Sigma) for 909 
15 min. Forelimbs were amputated above the elbow, and the bone and soft tissue 910 
were trimmed to produce a flat amputation surface. Animals were left to recover 911 
overnight in an aqueous solution of 0.5% sulfamerazine (Sigma). At specified 912 
time-points, the regenerating limbs were collected. Three ul of 5mg/ml AEBSF 913 
(Roche) and/or baculo virus expressing BMP4 or cherry was injected into the 914 
blastema at 6dpa and 9dpa. For EdU-labelling, animals were injected 915 
intraperitoneally with 50-100 µl of 1mg/ml EdU. All surgical procedures were 916 
performed according to the European Community and local ethics committee 917 
guidelines. 918 
Luciferase assay 919 
Smad-luc reporter (pGL3-BRE-“BMP Responsive Element”-Luciferase plasmid) 920 
was from Addgene, pGL3-basic and pRL-Renilla were from Promega. Dual 921 
Luciferase Assay system (Promega) was used to measure the luciferase activity 922 
in A1 myotubes, and in limbs. An Amaxa Nucleofector was used for 923 
electroporation of A1 myoblasts (Program T30) and the myoblasts were 924 
differentiated into myotubes over 7 days. Recombinant BMP4/7 with or without 925 
noggin was added into the cultured myotubes (500ng/ml). A1 myotubes were 926 
lysed after 24h using the passive lysis buffer provided in the dual luciferase 927 
reporter assay kit following the manufacturer’s instructions. The in vivo 928 
luciferase analysis procedures were modified from (Yun et al, 2013). In short, 929 
Smad-luc and pRL-Renilla plasmids were mixed at 10ug/ul. Three or 5 ul of 930 
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plasmid solutions were injected into blastemas or uninjured limbs, respectively. 931 
Electroporations were performed by NEPA21 electroporator with parallel fixed 932 
platinum electrodes using 10 pulses (duration: 100ms, voltage: 30volts 933 
decending). Tissues were collected 24h after electroporation and immediately 934 
homogenized in passive lysis buffer (Promega).Lysates were centrifuged to 935 
remove debris, and assayed according to the dual luciferase reporter protocol. 936 
The activities of the Smad-Luc reporter were normalized to the activity of the 937 
internal Renilla control and expressed as relative luciferase activity 938 
(Firefly/Renilla). 939 
Baculo virus production 940 
Production of pseudotyped baculovirus was as described in Nacu et al 2016. 941 
Baculovirus was pseudotyped with vsv-ged gene, which was inserted into the 942 
rescue vector under the baculovirus polyhedrin promoter.BMP4 or Cherry 943 
constructs were cloned into a rescue vector using standard restriction enzyme 944 
methods, and are expressed under the control of a CMV promoter. The 945 
generation of baculoviruses was carried out by co-transfection of the above-946 
mentioned rescue vector together with replication incompetent baculovirus DNA 947 
into SF9 ESF insect cell line. Upon culture expansion, recombinant baculovirus 948 
particles were collected, concentrated and purified using the sucrose gradient 949 
separation method. The titer was assessed in SF9ET cells, by means of end-point 950 
dilution assay. 951 
Immunohistochemistry 952 
Frozen sections (8 μm) were thawed at room temperature and fixed in 4% 953 
formaldehyde for 5 min. Sections were blocked with 5% donkey serum and 0.1% 954 
Triton-X for 30 min at room temperature. Sections were incubated with anti-GFP 955 
Formatted: English (U.S.)
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(Abcam 6673) and anti-MHC (DSHB) or anti-Phospho-Smad1/5/8 (Cell Signaling 956 
9511) overnight at 4°C and with secondary antibodies for 1 hour at room 957 
temperature. Antibodies were diluted in blocking buffer and sections were 958 
mounted in mounting medium (DakoCytomation) containing 5 µg/ml DAPI 959 
(Sigma). PhosSTOP (Roche) was used during Phospho-Smad1/5/8 staining 960 
process. EdU detection was performed according to (Salic and Mitchison, 2008). 961 
An LSM 700 Meta laser microscope with LSM 6.0 Image Browser software (Carl 962 
Zeiss) was used for confocal analyses. One in every 6 (Figure 3) or 10 (Figure 4) 963 
sections was selected and counted.  964 
 965 
QUANTIFICATION AND STATISTICAL ANALYSIS  966 
Error bars represent SEM unless otherwise indicated. Statistical analysis 967 
was performed using GraphPad Prism software.  968 
 969 
Analysis of in vitro myotube cell cycle entry data: 970 
The percentage of BrdU
+
 myotubes were counted and always presented 971 
as mean±SEM from n samples. In Figure 1C the sample size was n = 9 972 
samples for each condition. Each sample was derived from counting one 973 
separate well containing a median of 84 myotubes per well. In Figure 1E 974 
the sample size was n = 9 samples (SPRF, PrG bead dep. and SPRF, 975 
αBMP4 + PrG bead dep.) and n = 54 samples (αBMP4 eluate). Each 976 
sample was derived from counting one separate well containing a median 977 
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of 44 myotubes per well. In Figure 3A the sample size was n = 9 samples 978 
(control) and n = 15 samples (dnBMPR). Each sample was derived from 979 
counting one separate well containing a median of 41 myotubes per well. 980 
In Figure 4D the sample size was n = 3 in control and n = 6 in other 981 
treatments. Each sample was derived from counting of one separate well 982 
containing a median of 132 myotubes. The statistical significance was 983 
always analyzed by an unpaired, two-tailed Student’s t-test, (95% 984 
confidence intervals). Please refer to figures for p-values. 985 
 986 
Analysis of immunofluorescence staining data: 987 
The percentages of EdU
+
/YFP
+
 cells were counted and presented as 988 
mean±SEM, n = 4 limbs (Figure 3E), 8 limbs (Figure 4G), 6 limbs in 989 
PBS and 8 limbs in AEBSF (Figure S4B), 8 limbs (Figure S4C) per each 990 
treatment group. The statistical significance was analyzed by Student’s t-991 
test, (95% confidence intervals). Please refer to figures for p-values.  992 
 993 
Analysis of luciferase activity data: 994 
The in vitro luciferase activity data were presented as mean±SEM, n = 8 995 
samples (Figure 4A). Each plate contained 10
6
 cells and triplicate plates 996 
were averaged for each sample. The in vivo luciferase activity data were 997 
presented as mean±SEM, n = 5 limbs per each group (Figure 4B). The 998 
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statistical significance was analyzed by Student’s t-test, (95% confidence 999 
intervals). Please refer to figures for p-values. 1000 
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Figure S1. Bovine BMP4 co‐fractionates with serum‐derived myotube S‐phase 
re‐entry inducing activity. Relates to Figure 1. (A) Summary of purification steps and –fold enrichment of activity across the purification.  Specific activity of pooled peak fractions from each column step was measured as the described in Materials and Methods based on the myotube bioassay. The “fold purification” was 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based 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the fold increase in specific activity found 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the peak pool 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each chromatography step and “yield” was calculated 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the total amount of activity found 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the peak pool 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each 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BMP4 was quantitated by western 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commercial recombinant hBMP4/4 as standard protein.  (B) Top: silver stained reducing gel of peak fractions from the five column steps listed in (A). Equal amount of protein were loaded in each sample. 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lines 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standards are indicated at the top of the chart. Fractions that eluted within the markers for the excluded volume (blue dextran, 2000 kD) and the included volume (salt peak) were analyzed. Amongst others, ovalbumin (43 kD) and ribonuclease A (13.8 kD) were used as molecular weight standards. For western blotting, pools from three consecutive fractions were prepared and equal volumes of pooled fractions were separated by SDS‐PAGE in reducing conditions. The S‐phase re‐entry activity for the pooled samples was calculated by averaging the activity that was found from individually assaying the single fractions of each pool on newt myotubes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Serum BMPs are more potent than recombinant BMPs under serum‐
free conditions, BMP signaling is required for S‐phase re‐entry of newt 
myotubes and the potency of recombinant BMPs is increased after thrombin 
and plasmin treatment. Relates to Figure 1 and Figure 2. (A) Dose response curves under serum‐free conditions for recombinant bovine BMP4/4, BMP7/7 and BMP4/7 containing dimers produced by transfection of 293 cells compared to dose response for serum‐derived bovine BMP4‐containing dimers. BMP4 protein was quantitated by western blotting against a standard purified protein preparation. Square: Serum‐derived BMP2 and BMP4 (SPRF), Circle: recombinant BMP4/7 heterodimer, Diamond: recBMP4/4 plus recBMP7/7 mixture, Inverted triangle: recBMP7/7, Triangle: recBMP4/4. Data are presented as mean ± SEM (n = 3). (B) Noggin inhibits the S‐phase re‐entry activity in fetal calf serum (FCS). Inhibition of S‐phase re‐entry by addition of recombinant human noggin‐Fc, produced by transfection of HEK293 cells, to FCS. Data are presented as mean ± SEM (n = 3). (C) Dose response of untreated recombinant human BMP4/4 homodimer (circle, green, solid line) and after treatment with thrombin (triangle, blue, dotted line) or plasmin (square, red, dashed line). Data are presented as mean ± SEM (n = 3). (D) Dose response of untreated recombinant human BMP7/7 homodimer (circle, green, solid line) and after treatment with thrombin (inverted triangle, blue, dotted 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line) or plasmin (square, red, dashed line). BMPs are made in HEK293 cells. Data are presented as mean ± SEM (n = 3). 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Figure S3. Mapping the target sites for thrombin and plasmin in hBMP4/4 by 
Edman. Relates to Figure 2, Data S1 and Table S2. (A) N‐terminal peptides found along the BMP4 and BMP7 sequences after Edman degradation analysis of BMP4/4 and BMP4/7. The N‐terminus of untreated hBMP4/4 was verified in reducing conditions (pink ‐ SPKHH). Thrombin‐treated hBMP4/4 homodimer in the presence of DTT detected one main sequence ARKKN (green) suggesting cleavage at R8.   The plasmin treated BMP4/4 yielded two major N‐termini, KKNKN and NYQEMVV.  In the plasmin treated hBMP4/7 heterodimer five main sequences (orange) NYQEMVV and KKNKNCR, as well as MANVAEN, DLGWQDW and NMVVRAC were found, indicating that plasmin targets hBMP4 at R10 and K103, whereas BMP7 is targeted at R22, R48 and R129.  (B) Samples from panel (C) were applied to SDS‐PAGE in the presence or absence of DTT. For identification of hBMP4 versus hBMP7 peptides in hBMP4/7‐derived samples, hBMP4/4 ‐ untreated or after protease treatment ‐ was run as a size standard in reducing conditions. Arrows indicate hBMP peptides (black = hBMP4/7 heterodimer peptides, blue = hBMP4 monomeric peptides, red = hBMP7 monomeric peptides). As shown by silver staining in reducing conditions (+DTT), in the case of BMP4, thrombin (T) gives rise to a single band, suggesting a single cleavage event. In contrast plasmin (P) cleavage results in two bands, suggesting multiple cleavages. In the case of BMP7, both thrombin and plasmin give rise to two bands each. However, thrombin and plasmin derived bands run at different molecular weights, indicating different specificity of the proteases.  (C) Activity assay of bacterially expressed BMP4/7.  Bacterially expressed and purified recombinant hBMP4/7 was incubated with or without proteases (plasmin or thrombin). The specific activity of untreated and protease treated hBMP4/7 was measured in the newt myotube assay. Data are presented as mean ± SEM (n = 3).  (D) Multiple sequence alignment of human BMP2, BMP4, BMP5, BMP6 and BMP7. BMPs are sub‐grouped according to their sequence homology. Mature bovine BMP2 and BMP4 display sequence similarity. Mature bovine BMP5, BMP6 and BMP7 display sequence similarity. The alignments of mature bovine BMP protein sequences were obtained from using the ClustalW2 (http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2) algorithm with standard parameters. (E) Cartoon of mature human BMP4/4 homodimer. Arginine (R) and Lysine (K) residues are enlarged. BMP4 Monomers are connected by an intermolecular disulfide bond (brown dashed line) at Cysteine (C) C81. Three intramolecular disulfide bonds (green, dashed lines) are formed between C16‐C80, C45‐C113, C49‐C115 in each of the monomers. 
 
 
 
 
 
 
 
 
 
Figure S4.  Serine proteases act upstream of BMPs to promote cell cycle entry 
of dedifferentiating myofibers. Relates to Figure 4. (A) Representation of the experiment testing the effect of protease inhibition and BMP rescue on muscle dedifferentiation in vivo.  The plasmin/thrombin inhibitor AEBSF or control PBS was injected together with baculovirus overexpressing ΔN‐BMP4 or Cherry into the blastema at 6dpa and 9dpa. Cell‐cycle re‐entry was quantified by EdU incorporation in the YFP+ myofiber progeny at 13dpa. (B) AEBSF reduces the cell‐cycle re‐entry of YFP+ cells in the blastema. Data are presented as mean ± SEM (n = 6‐8 limbs). Significance calculated by Student’s t‐test. (C) Viral‐mediated overexpression of ΔN‐BMP4 rescues the suppression of muscle cell cycle re‐entry by AEBSF‐mediated protease inhibition. Data are presented as mean ± SEM (n = 8 limbs). Significance calculated by Student’s t‐test. 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Supplemental Tables  
Table S1 
N Protein Name Gene Identifier(s) 
Peptides Detected by Mass Spectrometry 
Sequence* m/z 
MASCOT 
peptide 
ions 
score 
 
1 
 
Bone 
Morphogenetic 
Protein 2 
 
 
gi|7c149642861 
gi|7c148744883 
gi|7c157279020 
gi|7c296481187 
gi|7c153850483 
 
K.NYQDMVVEGCGCR.- 
 
802.5 
 
64 
 
2 
 
Bone 
Morphogenetic 
Protein 4 
 
 
gi|7c57545008 
gi|7c68445390 
gi|7c114052743 
gi|7c109818952 
gi|7c86821122 
gi|7c296483082 
 
K.NYQEMVVEGCGCR.- 
K.NYQEMVVEGCGCR.- 
 
801.5 
809.3 
 
85 
63 
 
3 
 
Bone 
Morphogenetic 
Protein 5 
 
gi|7c194677539 
gi|7c297488876 
gi|7c296474598 
 
K.LNAISVLYFDDSSNVILK.K 
R.MSSVGDYNTSEQK.Q 
R.MSSVGDYNTSEQK.Q 
K.KHELYVSFR.D** 
K.HELYVSFR.D** 
 
 
1006.3 
723.6 
731.6 
394.0 
526.0 
 
70 
89 
91 
36 
33 
 
4 
 
Bone 
Morphogenetic 
Protein 6 
 
 
gi|7c194677896 
gi|7c297489529 
gi|7c296473962 
 
R.ASSASDYNSSELK.T 
 
680.1 
 
64 
 
5 
 
Bone 
Morphogenetic 
Protein 7 
 
 
gi|7c76633049 
gi|7c297481860 
gi|7c296480909 
 
R.VANVAENSSSDQR.Q 
K.KHELYVSFR.D** 
K.HELYVSFR.D** 
 
 
689.1 
394.0 
526.1 
 
84 
36 
33 
Table S1. Bone morphogenetic proteins identified in BMP4 
immunoprecipitation by mass spectrometry. Relates to Figure 2. (*)  M refers to methionine oxidized and C refers to cystein carbamidomethylated. (**) Stretches are identical in BMP5 and BMP7 sequences.           
Supplemental Tables (separate .xlsx files)  
Table S2. Edman sequencing of rhBMPs. Relates to Figure 2 Figure S3 and Data 
S1. Numerical data derived from Edman sequencing trace seen in Data S1 of rhBMP4/4 untreated/+plasmin/+thrombin as well as rhBMP4/7 + plasmin are presented for individual Edman cycles (1‐5).  
Table S3. Bovine BMP peptides identified by mass spectrometry. Relates to 
Figure 1 and Figure S1. Table of the 34 proteins identified by MS from the gel slice of the final purification step. Peptides were identified by mass spectrometry of a non‐reducing gel slice spanning 28‐39 kD. Bovine BMP peptides that were identified mapped onto protein sequences of the complete precursor protein. 
 
 
Supplemental Data (separate .pdf file) 
 
Data S1. Traces of Edman sequencing of rhBMPs. Relates to Figure 2, Figure S3 
and TableS2. Edman traces of rhBMP4/4 untreated/+plasmin/+thrombin as well as rhBMP4/7 + Plasmin are shown for individual Edman cycles (1‐5). Colored circles (red, green, orange, blue, pink) highlight major amino acid peaks identified for each individual cycle. The corresponding colored circles in successive traces delineate a peptide that matches a BMP peptide sequence. Black circles highlight minor abundance amino acids that could not be assigned to the BMP query sequence and are most likely contamination. 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Data S1. Traces of Edman sequencing of rhBMPs. Relates to Figure 2, Figure S3 
and TableS2.Edman traces of rhBMP4/4 untreated/+plasmin/+thrombin as well as rhBMP4/7 + Plasmin are shown for individual Edman cycles (1-5). Colored circles (red, green, 
orange, blue, pink) highlight major amino acid peaks identi�ied for each individual cycle. The corresponding colored circles in successive traces delineate a peptide that matches a BMP peptide sequence. Black circles highlight minor abundance amino acids that could not be assigned to the BMP query sequence and are most likely contamination.
